

Nanexa announces the result of the use of warrants of series TO2

Nanexa AB ("Nanexa" or "the Company") today announced the result of the use of warrants of series TO2, which were issued in connection with the Company's rights issue in February 2020. The result shows that a total of 2,956,588 warrants were used to subscribe for 2,956,588 new shares in the Company, corresponding to approximately 97.5 percent of the total number of issued warrants of series TO2.

In February 2020, Nanexa made a rights issue of units where every unit included four (4) shares and two (2) warrants of series TO2 free of charge. In total, 3,031,978 warrants of series TO2 were issued. Every warrant carried the right, during the subscription period between 1-15 February 2021, to subscribe for one (1) newly issued share at the subscription price of SEK 8.42 per share.

The subscription period is completed and the result shows that a total of 2,956,588 warrants were used to subscribe for 2,956,588 new shares in the Company, corresponding to approximately 97.5 percent of the total number of issued warrants of series TO2. This will bring a total of approximately SEK 24.9 million to Nanexa before transaction costs.

"The Board of Directors and I are very pleased with the high interest and the almost full subscription. We are grateful for the trust and look forward to an exciting year of value creation in 2021," says David Westberg, CEO of Nanexa.

Through the use of 2,956,588 warrants of series TO2, the number of shares and votes in the Company will increase by 2,956,588, from 21,910,346 to 24,866,934 shares and votes, and the share capital will increase by approximately SEK 382,645,63, from SEK 2,835,666.73 to approximately SEK 3,218,312.36. The dilution for shareholders that have not used any warrants to subscribe for new shares amounts to approximately 12 percent.

The interim shares that are issued in connection with redemption of warrants are estimated to be replaced by ordinary shares and to be taken up for trading within two weeks.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: david.westberg@nanexa.se

www.nanexa.com

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, a new and groundbreaking drug delivery system with great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.

Attachments

[Nanexa announces the result of the use of warrants of series TO2](#)